Autres langues CSPC Pharmaceutical Group Limited

Actions

1093

HK1093012172

Produits pharmaceutiques

Temps Différé Hong Kong S.E. Autres places de cotation 07:54:00 23/07/2026			Varia. 5j.	Varia. 1 janv.
8,360 ^HKD	-0,48%		-2,67%	-0,71%

22/07	CSPC Pharmaceutical Group Limited lance un essai clinique de phase II pour l'injection SYS6026 contre les lésions malpighiennes intra-épithéliales de haut grade du col de l'utérus liées aux HPV 16 ou 18 en Chine	CI
17/07	CSPC Pharmaceutical Group Limited annonce l'acceptation par la NMPA de la demande de mise sur le marché du Trastuzumab Envedotin injectable	CI

Autres langues

22/07	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial of Sys6026 Injection for HPV Type 16 or 18 Related Cervical High Grade Squamous Intraepithelial Lesion in China
17/07	CSPC Pharmaceutical Group Limited Announces New Drug Application for Trastuzumab Envedotin Injection Accepted by Nmpa
17/07	CSPC Pharma's Application for Breast Cancer Drug Candidate Accepted in China
16/07	CSPC Pharma Begins Two Drug Trials in China
15/07	CSPC Pharma's Breast Cancer Drug Combination Granted China Breakthrough Designation
14/07	CSPC Pharmaceutical Group Limited Announces Docetaxel for Injection (Albumin-Bound) and Anbenitamab Receives Breakthrough Therapy Designation in China for First-Line Treatment of Advanced HER2-Positive Breast Cancer Co-Developed by Shanghai JMT-BIO Technology Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd
07/07	Weight-loss drug developers line up to tap lucrative market as competition heats up
07/07	CSPC Pharma Begins Phase II Trial of Mixed Hyperlipidaemia Drug
07/07	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYH2070 Injection For Treatment Of Mixed Hyperlipidaemia At First Centre In China
02/07	European Stocks Surge, Oil Prices Drop; Defense, Luxury Shares Rally
02/07	CSPC Pharma Begins Tumor Drug Trial in China
02/07	AstraZeneca Collaborating With CSPC Pharma in siRNA Drug Deal Worth Up to $1.77 Billion
02/07	CSPC Pharma's Tumor Drug Gets Breakthrough Therapy Designation in China
02/07	CSPC Pharma Gets Marketing Nod for Anemia Drug in China
02/07	CSPC Pharma Gets China Nod for Trial of Herpes Zoster Vaccine
02/07	CSPC Pharma, AstraZeneca Enter Development Deal for Potential Renal Disease Drug Candidates
02/07	CSPC Pharmaceutical Group Limited Announces Iron Sucrose Injection Receives Marketing Approval
02/07	CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration for Recombinant Herpes Zoster Vaccine to Conduct Clinical Trial
02/07	CSPC Pharmaceutical Group Limited Officially Initiates Phase I Clinical Study of SYH2095 Tablets as Monotherapy or in Combination Regimens for the Treatment of Advanced Malignant Tumours in China
02/07	Chip Wreck Roils Asian Stock Markets
02/07	AstraZeneca signs CSPC China deal for experimental kidney disease drugs
02/07	China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug
02/07	CSPC Pharmaceutical Group Limited and AstraZeneca Enter into Collaboration, Option and License Agreement for the Development of siRNA Drugs
01/07	CSPC Pharmaceutical Begins Lung Cancer Trial in China
30/06	CSPC Pharmaceutical Group Limited Initiates Phase III Clinical Trial of SYS6010 in Combination with Enlonstobart for Adjuvant Treatment of Resected Stage II-IIIB Non-Small Cell Lung Cancer